More vitamin D, less bone fracture risk
Posted on: Wednesday, 25 March 2009, 20:09 CDT
Swiss researchers say higher doses of vitamin D daily may reduce bone fracture risk for the elderly.
Their analysis of research studies, published in the Archives of Internal Medicine, found doses higher than 400 international units per day reduced non-vertebral fractures by 20 percent and hip fractures by 18 percent.
Heike A. Bischoff-Ferrari of the University of Zurich Hospital in Switzerland and colleagues performed a meta-analysis on 12 previously published clinical trials of oral vitamin D supplements among adults age 65 and older. These double-blind randomized controlled trials involved non-spinal fractures in 42,279 participants -- including eight trials of 40,886 participants specifically studying hip fractures.
When the researchers studied the results of the trials, vitamin D supplements doses of 400 international units per day or lower did not reduce non-spinal or hip fracture risks. The greater reduction in risk was seen among trial participants whose blood levels of 25-hydroxyvitamin D -- a measure of blood vitamin D levels -- achieved a greater increase.
Higher doses of vitamin D should be explored in future research to optimize anti-fracture efficacy,
the study authors said in a statement. Our results do not support use of low-dose vitamin D with or without calcium in the prevention of fractures among older individuals.
Source: United Press International
Related Articles
- Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
- Inhibitex Reports Initiation of Multiple Ascending Dose Trial of FV-100 for Shingles
- Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA; LX1032 Multi-Dose Trial to Be Initiated in June
- EntreMed Starts Phase I Continuous Dosing Trial of Cancer Drug
- Chimerix Starts Multi-Dose Trial for Smallpox Infection
- Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
- Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women With History of Hip Fracture
- CytRx Announces Clinical Results From Its Rising Multiple Dose Trial With Arimoclomol for ALS
- Greer to Present Findings of Sublingual-Oral Immunotherapy Safety and Dosing Trials at 2006 American Academy of Allergy Asthma and Immunology Meeting
- Neurogen Announces Results of Phase I Multiple Ascending Dose Trial for Insomnia Drug
 |
 |
User Comments (0)
RSS Feeds